SAN DIEGO, June 2 /PRNewswire-FirstCall/ -- Orexigen(R) Therapeutics, Inc. (Nasdaq: OREX) a biopharmaceutical company focused on the treatment of obesity, today announced the schedule of its upcoming Contrave(R) (naltrexone sustained release (SR)/bupropion SR) presentations taking place at the American Diabetes Association (ADA) 69th Scientific Sessions, June 5-9, 2009, and the 91st Annual Meeting of the Endocrine Society (ENDO), June 10-13, 2009.
ADA: Ernest N. Morial Convention Center, New Orleans, LA.
Saturday, June 6: Embargo Lifts June 6 at 9:00 a.m. CT Oral Presentation Abstract: 37-OR Presenter: Thomas A. Wadden, Ph.D., University of Pennsylvania School of Medicine, Philadelphia, PA Title: "Naltrexone + Bupropion Combination Causes Significant Weight Loss: A 56-week Phase 3 Study" Time: 9:00 a.m. CT Location: Room 255 Monday, June 8: Embargo Lifts June 6 at 10:00 a.m. CT Poster Presentation* Abstract: 1731-P Presenter: Thomas A. Wadden, Ph.D., University of Pennsylvania School of Medicine, Philadelphia, Pa. Title: "Naltrexone + Bupropion Combination Causes Weight Loss and Improves Quality of Life" Time: 12:00 - 2:00 p.m. CT Location: Hall E Poster Presentation* Abstract: 1730-P Presenter: Samuel Klein, M.D., Washington University School of Medicine, St. Louis, Mo. Title: "Naltrexone + Bupropion Combination Causes Significant Weight Loss Without Worsening Psychiatric Symptoms" Time: 12:00 - 2:00 p.m. CT Location: Hall E * Posters will also be presented Sunday, June 7 from 6:30 - 7:45 p.m. CT at a Poster Reception in Hall E
ENDO: Walter E. Washington Convention Center, Washington, D.C.
Friday, June 12: Embargo Lifts June 12 at 11:15 a.m. ET Oral Presentation Abstract: OR18-5 Presenter: F. Xavier Pi-Sunyer, M.D., M.P.H., The New York Obesity Research Center, St. Luke's Roosevelt Hospital Center, New York, N.Y. Title: "Combination Therapy with Naltrexone + Bupropion Causes Significant Weight Loss and Improves Cardiometabolic Parameters in Obese Individuals: A Randomized Phase 3 Study Over 56 Weeks" Time: 11:15 a.m. ET Location: Room 152AB
About Orexigen Therapeutics
Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead combination product candidates targeted for obesity are Contrave(R), which is in Phase 3 clinical trials, and Empatic(TM), which is in the later stages of Phase 2 clinical development. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss. Further information about the Company can be found at http://www.orexigen.com.
|SOURCE Orexigen Therapeutics, Inc.|
Copyright©2009 PR Newswire.
All rights reserved